Modeling and predicting individual variation in COVID-19 vaccine-elicited antibody response in the general population
-
Published:2024-05-03
Issue:5
Volume:3
Page:e0000497
-
ISSN:2767-3170
-
Container-title:PLOS Digital Health
-
language:en
-
Short-container-title:PLOS Digit Health
Author:
Nakamura NaotoshiORCID, Kobashi Yurie, Kim Kwang Su, Park Hyeongki, Tani Yuta, Shimazu Yuzo, Zhao Tianchen, Nishikawa YoshitakaORCID, Omata Fumiya, Kawashima Moe, Yoshida Makoto, Abe Toshiki, Saito Yoshika, Senoo Yuki, Nonaka Saori, Takita Morihito, Yamamoto Chika, Kawamura Takeshi, Sugiyama Akira, Nakayama Aya, Kaneko Yudai, Jeong Yong Dam, Tatematsu Daiki, Akao Marwa, Sato YoshitakaORCID, Iwanami ShoyaORCID, Fujita Yasuhisa, Wakui Masatoshi, Aihara Kazuyuki, Kodama Tatsuhiko, Shibuya Kenji, Iwami ShingoORCID, Tsubokura Masaharu
Abstract
As we learned during the COVID-19 pandemic, vaccines are one of the most important tools in infectious disease control. To date, an unprecedentedly large volume of high-quality data on COVID-19 vaccinations have been accumulated. For preparedness in future pandemics beyond COVID-19, these valuable datasets should be analyzed to best shape an effective vaccination strategy. We are collecting longitudinal data from a community-based cohort in Fukushima, Japan, that consists of 2,407 individuals who underwent serum sampling two or three times after a two-dose vaccination with either BNT162b2 or mRNA-1273. Using the individually reconstructed time courses of the vaccine-elicited antibody response based on mathematical modeling, we first identified basic demographic and health information that contributed to the main features of the antibody dynamics, i.e., the peak, the duration, and the area under the curve. We showed that these three features of antibody dynamics were partially explained by underlying medical conditions, adverse reactions to vaccinations, and medications, consistent with the findings of previous studies. We then applied to these factors a recently proposed computational method to optimally fit an “antibody score”, which resulted in an integer-based score that can be used as a basis for identifying individuals with higher or lower antibody titers from basic demographic and health information. The score can be easily calculated by individuals themselves or by medical practitioners. Although the sensitivity of this score is currently not very high, in the future, as more data become available, it has the potential to identify vulnerable populations and encourage them to get booster vaccinations. Our mathematical model can be extended to any kind of vaccination and therefore can form a basis for policy decisions regarding the distribution of booster vaccines to strengthen immunity in future pandemics.
Funder
Japan Society for the Promotion of Science Japan Agency for Medical Research and Development JST-Mirai Program Moonshot Research and Development Program Ministry of Science and ICT, South Korea Shinnihon Foundation of Advanced Medical Treatment Research Secom Science and Technology Foundation The Japan Prize Foundation Kowa Company
Publisher
Public Library of Science (PLoS)
|
|